Search results for

Peter Ollier, Hong Kong

Pfizer has won a key victory in the Chinese courts over the patent for sildenafil citrate, the active ingredient in its impotence drug

The 2007 edition of the Americas IP Focus is published amid important changes in IP practice. Nowhere is this more true than in the Americas. In the US, Congress is debating fundamental changes to patent law, arising from concerns over the scope of protection and abuse of the vagaries of the patent system, while the Supreme Court has, in the past year, delivered four decisions of fundamental importance to IP owners. Meanwhile, new means of monetizing patents are being tested and the USPTO has introduced controversial reforms to address its backlog and delays in both the patent and trade mark fields.

Law firms and patent and trade mark agencies are reporting record levels of demand from IP clients. Managing IP published a list of the largest practices across the globe in its September 2007 issue. The tables for the US and Canada are reprinted here

Managing IP spoke to the UK's new minister for IP, Lord Triesman, to discuss the role of the IP Office, upholding the public domain and how to make the UK fake-free

The European Commission recently published figures for 2006 relating to seizures by national Customs authorities of goods infringing IP rights on their entry into the EU. These reveal a considerable increase in the number of counterfeit and pirated articles being seized generally, Customs seizing more than 250 million articles in 2006 compared with 75 million in 2005; but in particular highlight a rapid growth in the trade of counterfeit medicines.

The Dubai Court of First Instance recently ordered that an identical trade name be deleted from the Commercial Register as it violated the plaintiff's registered and well-known trade mark as well as its name.

Data exclusivity, a key IP concern for research-based pharmaceutical companies, was introduced into the Turkish legislation with the publication of the Regulation on Marketing Authorization for Medicinal Products for Human Use in January 2005. The regulation only relates to pharmaceuticals for human use and does not bring exclusivity on the test data relating to agricultural chemicals, such as pesticides or insecticide, to obtain authorization for marketing in the country.

Most of us who work with intellectual property know that there are a large number of patents out there that will never have a relevant impact on any business.

Under the interpretation of the rules put forth by the Intellectual Property Office of Singapore (IPOS), the extensions of time as of right under Rule 108(3) are not available under the slow track option.